Arrhythmias and cardiac stimulation

• Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death

  Aida Ribera, Emmanuel Giménez, Gerard Oristrell, Dimelza Osorio, Josep Ramón Marsal, Lidia García-Pérez, Mónica Ballesteros, Eduard Ródenas, Yassin Belahnech, Roxana Escalona, Núria Rivas, Ivo Roca-Luque, Ignacio Ferreira-González, Mireia Espallargues

  Rev Esp Cardiol. 2022;75:12-21

• Risk stratification of ventricular arrhythmias in repaired tetralogy of Fallot

  Nuria Rivas-Gándara, Jaume Francisco-Pascual, Antonia Pijuan-Domenech, Aida Ribera-Solé, Laura Dos-Subirá, Begoña Benito, Maria Terricabras, Jordi Pérez-Rodon, María Teresa Subirana, Alba Santos-Ortega, Ferran Roses-Noguer, Berta Miranda, Àngel Moya-Mitjans, Ignacio Ferreira-González

  Rev Esp Cardiol. 2021;74:935-42

• Safety of transvenous lead removal in adult congenital heart disease: a national perspective

  Xiaofan Guo, Robert M. Hayward, Eric Vittinghoff, Sun Yong Lee, Ian S. Harris, Mark J. Pletcher, Byron K. Lee

  Rev Esp Cardiol. 2021;74:943-52

• The RITHMI study: diagnostic ability of a heart rhythm monitor for automatic detection of atrial fibrillation

  Joaquín Osca Asensi, María Teresa Izquierdo de Francisco, Óscar Cano Pérez, María José Sancho Tello de Carranza, José Alberola Rubio, Carlos Planells Palop, José Vicente Lozano Vidal, Luis Martínez Dolz

  Rev Esp Cardiol. 2021;74:602-7

• Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry

  Aitor Uribarri, Iván J. Núñez-Gil, Álvaro Aparisi, Ramón Arroyo-Espliguero, Charbel Maroun Eid, Rodolfo Romero, Víctor M. Becerra-Muñoz, Gisela Feltes, María Molina, Marcos García-Aguado, Enrico Cerrato, Thamar Capel-Astrua, Emilio Alfonso-Rodríguez, Alex F. Castro-Mejía, Sergio Raposeiras-Roubín, Carolina Espejo, Nerea Pérez-Solé, Alfredo Bardají, Francisco Marín, Óscar Fabregat-Andrés, Fabrizio D’ascenzo, Francesco Santoro, Ibrahim Akin, Vicente Estrada, Antonio Fernández-Ortiz, Carlos Macaya, on behalf of HOPE COVID-19 investigators

  Rev Esp Cardiol. 2021;74:608-15

• Predictors of adoption and impact of evidence-based programming on the incidence of implantable cardioverter-defibrillator therapies

  Gerard Loughlin, Tomás Datino, Ángel Arenal, Ricardo Ruiz-Granell, Juan Miguel Sánchez-Gómez, Luisa Pérez, José Martínez-Ferrer, Javier Alzueta, Fernando Pérez-Lorente, Xavier Viñolas, María Luisa Fidalgo Andrés, Joaquín Fernández de la Concha

  Rev Esp Cardiol. 2021;74:296-302

• Emergency department attendance and reasons for consultation after cryoballoon ablation for pulmonary vein isolation of atrial fibrillation

  Francisco Cantero López, Ginés Elvira Ruiz, Pablo Peñafiel Verdú, Juan Martínez Sánchez, Juan José Sánchez Muñoz, Carmen Muñoz Esparza, David José Vázquez Andrés, Miguel Martínez Herrera, Francisco José García Almagro, Arcadi García Alberola

  Rev Esp Cardiol. 2021;74:233-7

• PET/CT with 18F-FDG in suspected intracardiac device-related infections: analysis of performance and diagnostic usefulness

  Begoña Rodríguez-Alfonso, Mercedes Mitjavila Casanovas, Víctor Castro Urda, Marta Cobo Marcos, Isabel Sánchez Romero, Antonio Ramos-Martínez

  Rev Esp Cardiol. 2021;74:238-46

• Atrioventricular block in patients undergoing treatment with bradycardic drugs. Predictors of pacemaker requirement

  Laura Jordán-Martínez, Ricardo Rivera-López, Francisco Bermúdez-Jiménez, Juan Jiménez-Jaimez, Javier Alzueta, Alberto Barrera-Cordero, Ricardo Rivera-Fernández, Manuel Jiménez-Navarro, Miguel Álvarez, Luis Tercedor

  Rev Esp Cardiol. 2020;73:554-60

• Effect of pulmonary vein catheter ablation on kidney function in patients with atrial fibrillation. A prospective cohort study

  Rosa Macías-Ruiz, Juan Jiménez-Jáimez, Miguel Álvarez-López, Manuel Molina-Lerma, Pablo Sánchez-Millán, Rosemary Wangensteen, Andrés Quesada, Antonio Osuna-Ortega, Luis Tercedor-Sánchez

  Rev Esp Cardiol. 2020;73:471-8

• Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project

  Adolfo Fontenla, María López-Gil, Juan Tamargo-Menéndez, Roberto Matía-Francés, Ricardo Salgado-Aranda, Juan Ramón Rey-Blas, Ángel Miracle-Blanco, Elena Mejía-Martínez, Agustín Pastor-Fuentes, Jorge Toquero-Ramos, Miguel Ángel Arias, Isabel Montilla, Agustín Gómez de la Cámara, Fernando Arribas, on behalf of the BRAKE-AF investigators

  Rev Esp Cardiol. 2020;73:368-75

• Performance of the Micra cardiac pacemaker in nonagenarians

  Amine El Amrani, Bieito Campos, Concepción Alonso-Martín, José M. Guerra-Ramos, Enrique Rodríguez-Font, Zoraida Moreno-Weidmann, Óscar Alcalde-Rodríguez, Francisco J. Méndez-Zurita, Miguel Santaló, Hildemari Espinosa-Viamonte, Xavier Viñolas

  Rev Esp Cardiol. 2020;73:307-12

• Change in neuron specific enolase levels in out-of-hospital cardiopulmonary arrest survivors as a simple and useful tool to predict neurological prognosis

  Agnès Rafecas, Jordi Bañeras, Jordi Sans-Roselló, José T. Ortiz-Pérez, Ferran Rueda-Sobella, Estevo Santamarina, Laia Milà, Alessandro Sionis, Carles Gaig, Cosme García-García, José A. Barrabés, David García-Dorado, Rosa-Maria Lidón

  Rev Esp Cardiol. 2020;73:232-40

• Neuron-specific enolase kinetics: an additional tool for neurological prognostication after cardiac arrest

  Pedro Martínez-Losas, Esteban López de Sá, Eduardo Armada, Sandra Rosillo, María Carmen Monedero, Juan Ramón Rey, Juan Caro-Codón, Antonio Buño Soto, José Luis López Sendón

  Rev Esp Cardiol. 2020;73:123-30

• Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study

  Manuel Anguita Sánchez, Vicente Bertomeu Martínez, Martín Ruiz Ortiz, Ángel Cequier Fillat, Inmaculada Roldán Rabadán, Javier Muñiz García, Lina Badimón Maestro, María Asunción Esteve Pastor, Francisco Marín Ortuño, on behalf of the FANTASIIA study investigators

  Rev Esp Cardiol. 2020;73:14-20

• Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)

  Óscar Cano, Alejandro Bellver, Adolfo Fontenla, Roger Villuendas, Pablo Peñafiel, Jaume Francisco-Pascual, José Luis Ibáñez, Vicente Bertomeu-González, Lorena García-Riesco, Javier García-Seara, Ángel Martínez-Brotons, David Calvo, Bieito Campos, José Enero, Antonio Peláez, José Martínez-Ferrer, Francisco Mazuelos, José Luis Moriñigo, Carmen Expósito, Ángel Arenal, Marta Pombo, Federico Segura, Agustín Pastor, Fernando Pérez, Ignacio Fernández-Lozano, Juan José González-Ferrer, Sara Moreno, Julia Martín-Fernández, José Ormaetxe, Ricardo Pavón, José María Tolosana, Jordi Mercé, Francisco-José García-Almagro, Miguel Álvarez, Alfonso Macías, Rafael Peinado, Cecilia Linde, Camilla Normand, Kenneth Dickstein

  Rev Esp Cardiol. 2019;72:1020-30

• Proposal for a Novel Score to Determine the Risk of Cardiac Implantable Electronic Device Infection

  Jorge Calderón-Parra, Enrique Sánchez-Chica, Ángel Asensio-Vegas, Ignacio Fernández-Lozano, Jorge Toquero-Ramos, Víctor Castro-Urda, Ana Royuela-Vicente, Antonio Ramos-Martínez

  Rev Esp Cardiol. 2019;72:806-12

• Diagnostic Yield and Economic Assessment of a Diagnostic Protocol With Systematic Use of an External Loop Recorder for Patients With Palpitations

  Jaume Francisco-Pascual, Alba Santos-Ortega, Ivo Roca-Luque, Nuria Rivas-Gándara, Jordi Pérez-Rodón, Laia Milà-Pascual, David García-Dorado, Àngel Moya-Mitjans

  Rev Esp Cardiol. 2019;72:473-8

• Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis

  Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza, M. José Martínez-Zapata

  Rev Esp Cardiol. 2019;72:305-16

• Novel Biomarkers in Cardiac Resynchronization Therapy: Hepatocyte Growth Factor Is an Independent Predictor of Clinical Outcome

  Péter Perge, András Mihály Boros, Szabolcs Szilágyi, Endre Zima, Levente Molnár, László Gellér, Zoltán Prohászka, Béla Merkely, Gábor Széplaki

  Rev Esp Cardiol. 2019;72:48-55